mirtazapine has been researched along with Pituitary Neoplasms in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " He had an ischemic stroke and developed a psychotic condition that was successfully treated by lowering the cabergoline and administering quetiapine and mirtazapine together." | 3.91 | Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report. ( Casulari, LA; de Castro, LF; de Fátima Magalhães Gonzaga, M; Kessler, IM; Mendonça, JL, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casulari, LA | 1 |
| de Castro, LF | 1 |
| Kessler, IM | 1 |
| Mendonça, JL | 1 |
| de Fátima Magalhães Gonzaga, M | 1 |
1 other study available for mirtazapine and Pituitary Neoplasms
| Article | Year |
|---|---|
Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
Topics: Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; | 2019 |